Gene Colice, MD, Richard J

Slides:

Advertisements

Similar presentations

A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay Jing Lin, PhD, Francesca M. Bruni,

Advertisements

Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy Yitzhak Katz, MD, Nelly Rajuan, MSc, Michael R. Goldberg,

Endoplasmic reticulum stress influences bronchial asthma pathogenesis by modulating nuclear factor κB activation So Ri Kim, MD, PhD, Dong Im Kim, MS, Mi.

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered- dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder.

Comparative outcomes of leukotriene receptor antagonists and long-acting β-agonists as add-on therapy in asthmatic patients: A population-based study

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery Albertien A.C. Aukema,

Risk of an asthma exacerbation after bariatric surgery in adults

Small-particle Inhaled Corticosteroid as First-line or Step-up Controller Therapy in Childhood Asthma Willem M.C. van Aalderen, MD, PhD, Jonathan Grigg,

Differential effects of maintenance long-acting β-agonist and inhaled corticosteroid on asthma control and asthma exacerbations Peter G. Gibson, MBBS(Hons),

The prevalence of severe refractory asthma

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD

Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies Stuart W Stoloff,

Severe winter asthma exacerbations can be prevented by omalizumab, but there is no carryover effect Peter D. Sly, MD, DSc, Julie Varghese, BHMS, PGDCTM,

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD

Is 9 more than 2 also in allergic airway inflammation?

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol Ian D. Pavord, DM, FRCP, Peter K. Jeffery,

Stanley J. Szefler, MD, Richard J. Martin, MD

Eric D. Bateman, MD, Helen K

Functional FCGR2B gene variants influence intravenous immunoglobulin response in patients with Kawasaki disease Sadeep Shrestha, PhD, Howard W. Wiener,

Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence L. Keoki Williams, MD, MPH, Edward L. Peterson,

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

A randomized multicenter study evaluating Xolair persistence of response after long- term therapy Dennis Ledford, MD, William Busse, MD, Benjamin Trzaskoma,

Tobacco smoke as a risk factor for allergic sensitization in adults: Conclusions of a systematic review and meta-analysis Beatriz Mónico, MSc, Jorge.

Safety of Fluticasone Propionate Prescribed for Asthma During Pregnancy: A UK Population-Based Cohort Study Rachel A. Charlton, PhD, Julia M. Snowball,

The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trials

Peter M. Wolfgram, MD, David B. Allen, MD

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

Etiology of asthma exacerbations

William J. Calhoun, MD, Tmirah Haselkorn, PhD, Dave P

Asthma treatment and asthma prevention: A tale of 2 parallel pathways

Effects of formoterol or salmeterol on impulse oscillometry in patients with persistent asthma Arvind Manoharan, MBChB, Alexander von Wilamowitz-Moellendorff,

Risk of congenital malformations for asthmatic pregnant women using a long-acting β2- agonist and inhaled corticosteroid combination versus higher-dose.

Intranasal triamcinolone use during pregnancy and the risk of adverse pregnancy outcomes Anick Bérard, MSc, PhD, Odile Sheehy, MSc, Marie-Laure Kurzinger,

High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects William Busse, MD, Sheldon Spector, MD, Karin Rosén,

Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: A real-world observational study David Price, FRCGP,

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

What are the best outcome measurements for atopic eczema

Cluster analysis and prediction of treatment outcomes for chronic rhinosinusitis Zachary M. Soler, MD, MSc, J. Madison Hyer, MS, Luke Rudmik, MD, MSc,

Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study Bradley E.

Justin R. Chen, MD, Brett L. Buchmiller, MD, David A. Khan, MD

Nicola A. Hanania, MB BS, MS, Bradley E. Chipps, MD, Noelle M

What is an “eosinophilic phenotype” of asthma?

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Autophagy: Nobel Prize 2016 and allergy and asthma research

A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma Gordon D. Raphael, MDa, Robert.

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered- dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder.

Mary F. Linehan, PhD, Timothy L. Frank, MD, Michelle L

Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down Eric D. Bateman, MD, Loretta Jacques, PhD,

Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe.

Protection by budesonide and fluticasone on allergen-induced airway responses after discontinuation of therapy Padmaja Subbarao, MD, MSc, Sandra C. Dorman,

The impact of a history of asthma on long-term outcomes of people with newly diagnosed chronic obstructive pulmonary disease: A population study Tetyana.

Risk of oral food challenges

Efficacy of nasal mometasone for the treatment of chronic sinonasal disease in patients with inadequately controlled asthma Anne E. Dixon, MA, BM BCh,

Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G

The Editors' Choice Journal of Allergy and Clinical Immunology

Päivi M. Salo, PhD, Samuel J. Arbes, DDS, MPH, PhD, Patrick W

Macrolide antibiotics and asthma treatment

A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis Warner Carr, MD, Jonathan Bernstein, MD, Phil Lieberman,

Environmental factors and eosinophilic esophagitis

Confirmation and improvement of criteria for clinical phenotyping in common variable immunodeficiency disorders in replicate cohorts Helen Chapel, MA,

The influence of health disparities on individual patient outcomes: What is the link between genes and environment? Andrea J. Apter, MD, MSc Journal.

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Modeling asthma exacerbations through lung function in children

Presentation transcript:

Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone Gene Colice, MD, Richard J. Martin, MD, Elliot Israel, MD, Nicolas Roche, MD, PhD, Neil Barnes, MBBS, FRCP, Anne Burden, MSc, Peter Polos, MD, Paul Dorinsky, MD, Elizabeth V. Hillyer, DVM, Amanda J. Lee, PhD, Alison Chisholm, MSc, Julie von Ziegenweidt, Francesca Barion, PhD, David Price, FRCGP Journal of Allergy and Clinical Immunology Volume 132, Issue 1, Pages 45-54.e10 (July 2013) DOI: 10.1016/j.jaci.2013.02.008 Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 ICS dose for matched cohorts, as prescribed on the index date for the initiation population. All differences in dose between the extrafine HFA-beclomethasone and fluticasone cohorts were statistically significant (P < .001). FP, Fluticasone propionate; HFA-BDP, hydrofluoroalkane–beclomethasone dipropionate. Journal of Allergy and Clinical Immunology 2013 132, 45-54.e10DOI: (10.1016/j.jaci.2013.02.008) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Proportion of patients in the initiation population by treatment cohort who achieved the overall control (risk and impairment) measure during the outcome year categorized by consumed ICS dose (ie, prescribed ICS divided by 365; A) and by MPR for ICSs (B). Exacerbation rates by MPR (C) and the proportion of patients who achieved the risk-domain asthma control measure by MPR (D) are shown also. Patient count percentages might not equal 100% because of rounding. FP, Fluticasone propionate; HFA-BDP, hydrofluoroalkane–beclomethasone dipropionate. Journal of Allergy and Clinical Immunology 2013 132, 45-54.e10DOI: (10.1016/j.jaci.2013.02.008) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Proportion of patients in the initiation population by treatment cohort who achieved the overall control (risk and impairment) measure during the outcome year categorized by consumed ICS dose (ie, prescribed ICS divided by 365; A) and by MPR for ICSs (B). Exacerbation rates by MPR (C) and the proportion of patients who achieved the risk-domain asthma control measure by MPR (D) are shown also. Patient count percentages might not equal 100% because of rounding. FP, Fluticasone propionate; HFA-BDP, hydrofluoroalkane–beclomethasone dipropionate. Journal of Allergy and Clinical Immunology 2013 132, 45-54.e10DOI: (10.1016/j.jaci.2013.02.008) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E1 Identification of eligible patients from the database for the initiation (A) and step-up (B) populations. Patients in the 2 treatment cohorts (HFA-beclomethasone and fluticasone) of each study population were then matched on 5 demographic and baseline criteria that could be predictive of or influence asthma control. COPD, Chronic obstructive pulmonary disease; DPI, dry powder inhaler; FP, fluticasone propionate; HFA-BDP, hydrofluoroalkane–beclomethasone dipropionate. Journal of Allergy and Clinical Immunology 2013 132, 45-54.e10DOI: (10.1016/j.jaci.2013.02.008) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E1 Identification of eligible patients from the database for the initiation (A) and step-up (B) populations. Patients in the 2 treatment cohorts (HFA-beclomethasone and fluticasone) of each study population were then matched on 5 demographic and baseline criteria that could be predictive of or influence asthma control. COPD, Chronic obstructive pulmonary disease; DPI, dry powder inhaler; FP, fluticasone propionate; HFA-BDP, hydrofluoroalkane–beclomethasone dipropionate. Journal of Allergy and Clinical Immunology 2013 132, 45-54.e10DOI: (10.1016/j.jaci.2013.02.008) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E2 ICS dose for matched cohorts as prescribed on the index date for the step-up population. All differences in dose between the extrafine HFA-beclomethasone and fluticasone cohorts were statistically significant (P < .001). FP, Fluticasone propionate; HFA-BDP, hydrofluoroalkane–beclomethasone dipropionate. Journal of Allergy and Clinical Immunology 2013 132, 45-54.e10DOI: (10.1016/j.jaci.2013.02.008) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E3 Proportion of patients in the step-up population by treatment cohort who achieved risk-domain asthma control (A) and exacerbation rates (B) during the outcome year categorized by MPR for ICS. FP, Fluticasone propionate; HFA-BDP, hydrofluoroalkane–beclomethasone dipropionate. Journal of Allergy and Clinical Immunology 2013 132, 45-54.e10DOI: (10.1016/j.jaci.2013.02.008) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions